7th Jul 2016 07:50
LONDON (Alliance News) - Life sciences firm ValiRx PLC on Thursday said it has sold the use of rights for its TRAC Technology for EUR800,000.
ValiRx has sold its ValiRx (Finland) Oy subsidiary, which owns the TRAC technology, to German biotechnology firm Sovicell Science for Life GmbH. TRAC is a cancer diagnosis technology.
"This transaction represents an exciting commercialisation of a part of our portfolio, and this deal will free up resource and management time," said ValiRx Chief Executive Satu Vainikka.
ValiRx shares were up 3.0% to 7.85 pence Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx